Horizon Buys AstraZeneca Spinout for $3 Billion to Broaden Rare Disease Pipeline
Horizon Therapeutics, which is well known for its rare disease portfolio, has decided to take over AstraZeneca spinout Viela Bio. The acquisition worth $3 billion guarantees Horizon a package of …
Read More